每经AI快讯，有投资者在投资者互动平台提问：了解到公司的产品质量已满足《欧洲药典》，请问贵 公司近两年是否有出口到欧盟地区呢 凯因科技（688687.SH）11月18日在投资者互动平台表示，公司会推动海外市场的战略布局，探索国际 市场，业务暂未覆盖欧盟地区。 （文章来源：每日经济新闻） ...

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

证券日报网讯凯因科技11月17日在互动平台回答投资者提问时表示，截至2025年11月10日，公司股东人 数为13033户。 ...

证券代码：688687 证券简称：凯因科技 公告编号：2025-035 北京凯因科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 11 月 12 日 （二） 股东会召开的地点：北京市北京经济技术开发区荣京东街 6 号 3 号楼会 议室 | 1、出席会议的股东和代理人人数 | 95 | | --- | --- | | 普通股股东人数 | 95 | | 2、出席会议的股东所持有的表决权数量 | 43,443,869 | | 普通股股东所持有表决权数量 | 43,443,869 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 25.4140 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 25.4140 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次会议由公司董事会召集，董 ...

广东信达律师事务所 股东大会法律意见书 深圳市福田区益田路 6001 号太平金融大厦 11、12 楼 邮政编码：518038 11/12/F, Tai Ping Finance Tower, 6001 Yitian Road, Futian District, Shenzhen, P. R. China 电话(Tel)：(0755)88265288 传真(Fax) ：(0755) 83265537 电子邮件（E-mail）：info@sundiallawfirm.com 网站（Website）：www.sundiallawfirm.com 广东信达律师事务所 关于北京凯因科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 信达科会字[2025]第 051 号 致：北京凯因科技股份有限公司 广东信达律师事务所（以下简称"信达"）接受北京凯因科技股份有限公司 （下称"贵公司"）的委托，指派律师参加了贵公司 2025 年第一次临时股东大 会（下称"本次股东大会"），并进行了必要的验证工作。 信达律师根据《中华人民共和国公司法》（下称"《公司法》"）、《上市 公司股东会规则》（下称"《股东会规则》"）等法 ...

北京凯因科技股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 2025 年第一次临时股东大会 会议资料 二○二五年十一月 1 北京凯因科技股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 2025 年第一次临时股东大会会议须知 | 3 | | --- | --- | | 2025 年第一次临时股东大会会议议程 | 5 | | 议案一：关于取消监事会、修订《公司章程》并办理工商变更登记的议案 | ... 8 | | 议案二：关于修订及制定公司部分治理制度的议案 | 9 | 为保障北京凯因科技股份有限公司（以下简称"公司"）全体股东的合法权 益，维护股东大会的正常秩序，保证股东大会如期、顺利召开，根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》《北京凯因科 技股份有限公司章程》（下称《公司章程》）等有关规定，特制定本须知。 一、会议期间，全体出席人员应以维护股东的合法权益、保证股东大会的正 常秩序和议事效率为原则，认真履行法定义务，自觉遵守股东大会纪律，不得侵 犯公司和其他股东的合法权益，不得扰乱 ...

Core Viewpoint - 凯因科技 is a domestic innovative pharmaceutical company focused on viral and immune diseases, with several commercialized products and a strong market position in the industry [1] Group 1: Business Performance - In Q3 2025, 凯因科技 reported revenue of 927 million yuan, ranking 15th among 34 companies in the industry, with the industry leader, 长春高新, generating 9.807 billion yuan [2] - The company's net profit for the same period was 112 million yuan, ranking 13th in the industry, with the top performer, 通化东宝, achieving 1.188 billion yuan [2] - The revenue composition includes 62.13% from chemical drugs (352 million yuan), 37.44% from biological drugs (212 million yuan), and minimal contributions from technical services and CMO/CDMO [2] Group 2: Financial Ratios - As of Q3 2025, 凯因科技's asset-liability ratio was 36.36%, higher than the previous year's 29.10% and the industry average of 26.88% [3] - The gross profit margin for the same period was 83.09%, an increase from 81.94% year-on-year and above the industry average of 70.17% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 6.30% to 13,100, while the average number of circulating A-shares held per shareholder decreased by 5.93% [5] - The top ten circulating shareholders saw a change, with 中庚价值领航混合 exiting the list [5] Group 4: Executive Compensation - The chairman, 周德胜, received a salary of 4.232 million yuan in 2024, a slight increase from 4.21 million yuan in 2023 [4] Group 5: Research and Development - In H1 2025, 凯因科技 invested 71.41 million yuan in R&D, representing 12.61% of its revenue, with several products entering clinical stages [5] - The company aims to maintain its market advantage with established products while increasing R&D expenditures for future growth [5][6]

Core Insights - Pension accounts have appeared in the top ten circulating shareholder lists of HaiTai New Light, DingTong Technology, Rejing Biology, and KaiYin Technology by the end of the third quarter [1] Group 1: Pension Holdings - The Basic Pension Insurance Fund 802 Combination is the fourth largest circulating shareholder of HaiTai New Light, holding 5.0346 million shares, accounting for 4.20% of circulating shares [1] - The Basic Pension Insurance Fund 1906 Combination and 16052 Combination are the seventh and ninth largest shareholders of DingTong Technology, with a total holding of 1.5174 million shares, representing 1.09% of circulating shares [1] - The Basic Pension Insurance Fund 16022 Combination is the ninth largest shareholder of Rejing Biology, holding 1.5001 million shares, which is 1.62% of circulating shares [1] - The Basic Pension Insurance Fund 2009 Combination is the eighth largest shareholder of KaiYin Technology, with a holding of 872.6 thousand shares, accounting for 0.51% of circulating shares [1] Group 2: Market Value of Holdings - The market value of HaiTai New Light's pension holdings is approximately 250.22 million [1] - The market value of DingTong Technology's pension holdings is approximately 144.02 million [1] - The market value of Rejing Biology's pension holdings is approximately 254.90 million [1] - The market value of KaiYin Technology's pension holdings is approximately 2.44 million [1]

Core Points - The company announced the convening of the fourth session of the seventh employee representative assembly on October 23, 2025 [1] - The assembly will review and approve the election of the sixth board of directors' employee director [1] - Ms. Wang Huan was elected as the employee director of the sixth board of directors through a democratic election by the employee representative assembly [1]

Core Insights - The company reported a revenue of 927 million yuan for the first three quarters of 2025, representing a year-on-year decline of 8.29% [1] - The net profit attributable to shareholders was 103 million yuan, down 5.14% year-on-year [1] - The non-recurring net profit stood at 100 million yuan, reflecting a year-on-year decrease of 9.05% [1] - The basic earnings per share were 0.612 yuan [1]